Journal
MAYO CLINIC PROCEEDINGS
Volume 88, Issue 6, Pages 544-551Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.mayocp.2013.02.007
Keywords
-
Categories
Ask authors/readers for more resources
Objective: To evaluate the effects of L-carnitine compared with placebo or control on morbidity and mortality in the setting of acute myocardial infarction. Methods: A systematic review and meta-analysis of 13 controlled trials (N = 3629) was conducted to determine the effects of L-carnitine vs placebo or control on mortality, ventricular arrhythmias (VAs), angina, heart failure, and reinfarction. These trials were identified via searches of the Ovid MEDLINE, PubMed, and Excerpta Medica (Embase) databases between May 1, 2012, and August 31, 2012. Results: Compared with placebo or control, L-carnitine was associated with a significant 27% reduction in all-cause mortality (odds ratio, 0.73; 95% CI, 0.54-0.99; P = .05; risk ratio [RR], 0.78; 95% CI, 0.60-1.00; P = .05), a highly significant 65% reduction in VAs (RR, 0.35; 95% CI, 0.21-0.58; P<.0001), and a significant 40% reduction in the development of angina (RR, 0.60; 95% CI, 0.50-0.72; P<.00001), with no reduction in the development of heart failure (RR, 0.85; 95% CI, 0.67-1.09; P = .21) or myocardial reinfarction (RR, 0.78; 95% CI, 0.41-1.48; P = .45). Conclusion: Compared with placebo or control, L-carnitine is associated with a 27% reduction in all-cause mortality, a 65% reduction in VAs, and a 40% reduction in anginal symptoms in patients experiencing an acute myocardial infarction. Further study with large randomized controlled trials of this inexpensive and safe therapy in the modern era is warranted. (C) 2013 Mayo Foundation for Medical Education and Research
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available